COST-EFFECTIVENESS ANALYSIS OF PLUS ASPIRIN VS PLACEBO PLUS ASPIRIN IN THE TREATMENT OF ISCHEMIC STROKE BASED ON A RANDOMIZED CLINICAL TRIAL

被引：0
|
作者：
Xiang, Y. [1 ]
Fan, W. [2 ]
Zhou, L. [3 ]
Guo, Z. [3 ]
Zhou, N. [3 ]
Yang, N. [3 ]
Hu, M. [3 ]
机构：
[1] Sichuan Univ, Chengdu 51, Peoples R China
[2] West China Second Univ Hosp, Chengdu, Peoples R China
[3] Sichuan Univ, Chengdu, Peoples R China
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV21
引用
收藏
页码：S93 / S93
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone
    Rothberg, M
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (06) : 464 - 464
  • [2] Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost-effectiveness analysis
    Shah, H
    Gondek, K
    CLINICAL THERAPEUTICS, 2000, 22 (03) : 362 - 370
  • [3] The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective
    Andre Lamy
    John Eikelboom
    Wesley Tong
    Fei Yuan
    Shrikant I. Bangdiwala
    Jackie Bosch
    Stuart Connolly
    Eva Lonn
    Gilles R. Dagenais
    Kelley R. H. Branch
    Wei-Jhih Wang
    Deepak L. Bhatt
    Jeffrey Probstfield
    Georg Ertl
    Stefan Störk
    P. Gabriel Steg
    Victor Aboyans
    Isabelle Durand-Zaleski
    Lars Ryden
    Salim Yusuf
    American Journal of Cardiovascular Drugs, 2024, 24 : 117 - 127
  • [4] The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective
    Lamy, Andre
    Eikelboom, John
    Tong, Wesley
    Yuan, Fei
    Bangdiwala, Shrikant I.
    Bosch, Jackie
    Connolly, Stuart
    Lonn, Eva
    Dagenais, Gilles R.
    Branch, Kelley R. H.
    Wang, Wei-Jhih
    Bhatt, Deepak L.
    Probstfield, Jeffrey
    Ertl, Georg
    Stoerk, Stefan
    Steg, P. Gabriel
    Aboyans, Victor
    Durand-Zaleski, Isabelle
    Ryden, Lars
    Yusuf, Salim
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2024, 24 (01) : 117 - 127
  • [5] Cost-Effectiveness Analysis of Ginkgolide Injection in the Treatment of Ischemic Stroke Based on a Randomized Clinical Trial
    Xiang, Yuliang
    Yang, Nan
    Guo, Zhaoting
    Zhou, Li
    Guo, Jeff Jianfei
    Hu, Ming
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2021, 27 (04) : 331 - 341
  • [6] Cilostazol plus Aspirin vs. Clopidogrel plus Aspirin in Acute Minor Stroke or Transient Ischemic Attack
    Huang, Hsin-Yi
    Chen, Jia-Hung
    Chi, Nai-Fang
    Chen, You-Chia
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2024, 31 (06) : 904 - 916
  • [7] Nadroparin plus aspirin versus aspirin alone in the treatment of acute ischemic stroke
    Sarama, GRK
    Roy, AK
    NEUROLOGY INDIA, 2003, 51 (02) : 208 - 210
  • [8] Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial
    Tank, Amarjeet
    Johnston, S. Claiborne
    Jain, Ritika
    Amarenco, Pierre
    Mellstrom, Carl
    Rikner, Klas
    Denison, Hans
    Ladenvall, Per
    Knutsson, Mikael
    Himmelmann, Anders
    Evans, Scott R.
    James, Stefan
    Molina, Carlos A.
    Wang, Yongjun
    Ouwens, Mario
    BMJ NEUROLOGY OPEN, 2023, 5 (02)
  • [9] Argatroban plus aspirin versus aspirin in acute ischemic stroke
    Chen, Lei
    Cao, Shanshan
    Yang, Junxiu
    NEUROLOGICAL RESEARCH, 2018, 40 (10) : 862 - 867
  • [10] Cost-effectiveness of clopidogrel plus aspirin vs. aspirin alone for secondary-prevention of cardiovascular events: Results from the CHARISMA trial
    Chen, Jersey
    Bhatt, Deepak L.
    Schneider, Elizabeth
    Shi, Chunxue
    Caro, Jaime
    Proskorovsky, Irina
    Hacke, Werner
    Fox, Keith A.
    Cohen, David J.
    CIRCULATION, 2006, 114 (18) : 826 - 826
12345